{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000084","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.481712+00:00","generated_at":"2026-06-01T09:42:27.739384+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis","bullets":["FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.","RMAT designation provides fast track and breakthrough therapy benefits, enabling expedited FDA interactions and development.","Topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in MG expected mid-2024.","Descartes-08 previously received FDA Orphan Drug Designation for MG.","Phase 2a data (Jan 2024) showed durable autoantibody depletion and clinically meaningful MG severity score improvements over 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000084","json":"https://secwatch.observer/filing/0001453687-24-000084.json","markdown":"https://secwatch.observer/filing/0001453687-24-000084.md","text":"https://secwatch.observer/filing/0001453687-24-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/0001453687-24-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/rnac-20240522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:42:27.739384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}